1 citations
,
August 2002 in “Zeitschrift für Hautkrankheiten” Male androgenetic alopecia involves hair follicle miniaturization due to DHT, with potential treatments using inhibitors and blockers.
38 citations
,
January 2012 in “Annales de Toxicologie Analytique” Many black market drugs for bodybuilders are fake and mislabeled.
1 citations
,
October 2012 in “Gynäkologische Endokrinologie” The document concludes that proper diagnosis and individualized treatment are crucial for managing androgenization in women effectively.
October 2010 in “Journal of Men's Health” Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.
January 2025 in “Reactions Weekly” November 2024 in “Reactions Weekly” May 2023 in “Reactions Weekly” December 1976 in “PubMed” Androgens affect skin conditions like acne and hirsutism, treatable with hormone therapy and other methods.
June 2023 in “Clinica Chimica Acta” Finasteride and dutasteride effectively reduce DHT in hair, which may help evaluate their treatment success for hair loss.
6 citations
,
May 1997 in “Journal of Dermatological Science” Researchers found a gene in hamsters that responds to male hormones and may be indirectly controlled by them.
408 citations
,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
8 citations
,
January 1987 in “Gynecological Endocrinology” Flutamide, an antiandrogen, has minimal impact on female rat endocrine systems and does not significantly change their reproductive cycles.
1 citations
,
November 2007 in “Neuro-chirurgie/Neurochirurgie” Cyproterone acetate is a safe treatment that causes modest feminization in transgender female adolescents, and works better with added estrogens.
20 citations
,
January 2018 in “Expert Opinion on Drug Safety” Personalized treatment with inhibitors, minoxidil, and laser therapy helps hair loss.
August 2025 in “Endokrynologia Polska” January 2026 in “Open Science Framework” Oral and topical 5-alpha reductase inhibitors affect DHT levels and hair density differently in treating hair loss.
41 citations
,
July 2001 in “PubMed” Estrogens can reduce DHT production in hair follicles, but are less effective than finasteride and progesterone.
October 2016 in “Letters in Drug Design & Discovery”
5 citations
,
January 1985 in “Archives of Dermatology” Skin creams that block male hormones may help with hair growth, hair loss, and acne.
17 citations
,
December 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists found new, better-working inhibitors for a hormone-related enzyme.
June 2024 in “Journal of cosmetic dermatology” Dutasteride is the most studied alternative drug for androgenetic alopecia, but more high-quality research is needed.
1 citations
,
June 2022 in “Frontiers in Neuroanatomy” Early hormones shape sex-specific differences in rat glands.
4 citations
,
April 2001 in “Experimental Dermatology” Using single dermal papillae is unreliable for analyzing androgen metabolism in hair follicles.
3 citations
,
February 2021 in “Molecules” A new method was created to test the effectiveness of Dihydrotestosterone (DHT) inhibitors, like finasteride and dutasteride, in human and fish cells. The results showed fish cells are more sensitive to these treatments, and dutasteride works better than finasteride in all tested cells.
19 citations
,
September 2013 in “Psychoneuroendocrinology” Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.
2 citations
,
May 2019 in “PubMed” Oral finasteride and dutasteride may negatively affect erectile function in rats.
7 citations
,
April 2000 in “Archives of Pathology & Laboratory Medicine”
15 citations
,
January 2017 in “Advances in Experimental Medicine and Biology” 5α-Reductase inhibitors can negatively affect male sexual function and, in some cases, significantly reduce sperm count, but these effects may be reversible.
July 2022 in “British Journal of Dermatology”